Gh Research Plc ( (GHRS) ) has released its Q3 earnings. Here is a breakdown of the information Gh Research Plc presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GH Research PLC, a clinical-stage biopharmaceutical company, is focused on developing innovative treatments for depression, particularly targeting treatment-resistant depression (TRD) with its proprietary mebufotenin therapies. In its latest earnings report, GH Research highlighted significant progress in its clinical trials and financial standing. The company reported a cash position of $293.9 million as of September 30, 2025, and ongoing engagement with the FDA regarding its GH001 IND application. Key achievements include meeting the primary endpoint in a Phase 2b trial for GH001, showing a significant reduction in depression scores, and presenting long-term safety and efficacy data at a major conference. Financially, the company saw an increase in research and development expenses to $10.6 million, and general administrative expenses rose to $6.0 million, resulting in a net loss of $14.0 million for the quarter. Looking ahead, GH Research remains committed to advancing its clinical programs, with plans to initiate a global pivotal program in 2026, reflecting a positive outlook for future developments.